ATMI, Inc., a provider of single-use bioprocess solutions, has invested in sterile connector and sterile fill technology developed by Medical Instill Technologies (Medinstill), a company dedicated to developing solutions for the transfer and packaging of high purity fluids at unmatched safety levels.

The investments focus on the INTACT family of products developed by Medinstill. These technologies will be deployed in sterile filling, sterile multiple-dose dispensing, sterile transfer, and packaging sterilization solutions that address current critical issues in the pharmaceutical, biotech, and healthcare industries.

“ATMI has a strong history of internal innovation as well as collaboration with other innovators,” said Doug Neugold, chief executive officer of ATMI. “Collaboration with Medinstill is another great example of this strategy. Through this investment, we will develop a suite of products that address critical issues from our customers’ perspective as they continue to adopt single-use technology and other new inventions. Our customers are looking for ways to reduce cost, minimize time to market and increase manufacturing flexibility. The INTACT solutions that we are developing with Medinstill enable efficiencies that will help us help them realize their objectives.”

ATMI and Medinstill have formed a joint venture to market and manufacture INTACT Filler technology for the biopharmaceutical industry. The technology is scalable from small lots in benchtop systems to industrial scales that enable the global biopharma and vaccine markets. ATMI has exclusively licensed INTACT Connector technology technology for the biopharma industry and will directly commercialize the connector products once development activity is completed.